This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 2006 Jul;2(3):150-2.

doi: 10.1016/j.jalz.2006.03.013.

Disease-modifying treatments for Alzheimer's disease: a perspective based on experience with R-Flurbiprofen

Gordon K Wilcock¹

Affiliations

Affiliation

¹ University of Bristol, Department of Clinical Science at North Bristol, Department of Care of the Elderly, Frenchay Hospital, Bristol, UK. wilcock@doctors.org.uk

PMID: 19595874
DOI: 10.1016/j.jalz.2006.03.013

Disease-modifying treatments for Alzheimer's disease: a perspective based on experience with R-Flurbiprofen

Gordon K Wilcock. Alzheimers Dement. 2006 Jul.

. 2006 Jul;2(3):150-2.

doi: 10.1016/j.jalz.2006.03.013.

Author

Gordon K Wilcock¹

Affiliation

¹ University of Bristol, Department of Clinical Science at North Bristol, Department of Care of the Elderly, Frenchay Hospital, Bristol, UK. wilcock@doctors.org.uk

PMID: 19595874
DOI: 10.1016/j.jalz.2006.03.013

No abstract available

PubMed Disclaimer

Similar articles

Defining and labeling disease-modifying treatments for Alzheimer's disease.
Cummings JL. Cummings JL. Alzheimers Dement. 2009 Sep;5(5):406-18. doi: 10.1016/j.jalz.2008.12.003. Alzheimers Dement. 2009. PMID: 19751920
Commentary on "Health economics and the value of therapy in Alzheimer's disease." Value therapy for Alzheimer's disease--a European perspective.
Vellas B, Froelich L, Sampaio C. Vellas B, et al. Alzheimers Dement. 2007 Jul;3(3):152-6. doi: 10.1016/j.jalz.2007.04.382. Alzheimers Dement. 2007. PMID: 19595930
Relevance of the evaluation criteria used in clinical trials for Alzheimer's disease.
Truffinet P, Bordet R, Ménard J. Truffinet P, et al. Therapie. 2009 May-Jun;64(3):139-8. doi: 10.2515/therapie/2009020. Epub 2009 Aug 13. Therapie. 2009. PMID: 19671425 Review. English, French.
Commentary on "Health economics and the value of therapy in Alzheimer's disease." Report from the Alzheimer's Association Research Roundtable on patient-reported outcomes and dementia research.
Frank LB. Frank LB. Alzheimers Dement. 2007 Jul;3(3):162-5. doi: 10.1016/j.jalz.2007.04.383. Alzheimers Dement. 2007. PMID: 19595932
Cholinesterase inhibition: is there evidence for disease-modifying effects?
Shanks M, Kivipelto M, Bullock R, Lane R. Shanks M, et al. Curr Med Res Opin. 2009 Oct;25(10):2439-46. doi: 10.1185/03007990903209332. Curr Med Res Opin. 2009. PMID: 19678754 Review.

See all similar articles

Cited by

Aspirin, steroidal and non-steroidal anti-inflammatory drugs for the treatment of Alzheimer's disease.
Jaturapatporn D, Isaac MG, McCleery J, Tabet N. Jaturapatporn D, et al. Cochrane Database Syst Rev. 2012 Feb 15;2012(2):CD006378. doi: 10.1002/14651858.CD006378.pub2. Cochrane Database Syst Rev. 2012. PMID: 22336816 Free PMC article.
Substrate-selective COX-2 inhibition as a novel strategy for therapeutic endocannabinoid augmentation.
Hermanson DJ, Gamble-George JC, Marnett LJ, Patel S. Hermanson DJ, et al. Trends Pharmacol Sci. 2014 Jul;35(7):358-67. doi: 10.1016/j.tips.2014.04.006. Epub 2014 May 18. Trends Pharmacol Sci. 2014. PMID: 24845457 Free PMC article. Review.

LinkOut - more resources

Full Text Sources
- Elsevier Science
- Wiley